TARGETING THE SARCOMERE TO IMPACT HEART FUNCTION

Omecamtiv Mecarbil

Cardiac myosin activator

Omecamtiv mecarbil is a selective small molecule cardiac myosin activator. Omecamtiv mecarbil is designed to directly target the contractile mechanism, or pumping function of the heart. By stimulating cardiac myosin, a protein responsible for converting chemical energy into the mechanical force that helps the heart contract, omecamtiv mecarbil may improve cardiac muscle performance. Preclinical research has shown that cardiac myosin activators increase cardiac contractility without affecting intracellular myocyte calcium concentrations or myocardial oxygen consumption.

Omecamtiv mecarbil is currently the subject of COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure), a confirmatory Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure (HF) with severely reduced ejection fraction.

Learn more about clinical trials for omecamtiv mecarbil

Omecamtiv mecarbil is an investigational product and is not approved by any regulatory agency. Safety and effectiveness have not been established.